# Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

> **NCT03720496** · PHASE1 · UNKNOWN · sponsor: **Timmune Biotech Inc.** · enrollment: 6 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell

## Interventions

- **BIOLOGICAL:** CD19-TriCAR-T

## Key facts

- **NCT ID:** NCT03720496
- **Lead sponsor:** Timmune Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720496, "Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03720496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*